Teva Pharmaceuticals USA is recalling one lot of Mesalamine Delayed-Release Tablets (1.2 gram), a prescription medication used to treat certain bowel conditions. Approximately 3,695 bottles, each containing 120 tablets, are affected after stability testing showed the tablets did not dissolve properly. If the medication does not dissolve as intended, it may not be absorbed correctly by the body, potentially reducing the effectiveness of the treatment.
The tablets failed 'dissolution specifications,' meaning the medication may not release the active ingredient into the body at the correct rate or location in the digestive tract. This can lead to a lack of therapeutic effect, potentially causing a relapse or worsening of the patient's underlying inflammatory bowel symptoms.
Healthcare consultation and pharmacy refund
If you or a family member were harmed by this recalled product, you may have legal rights. Consider consulting a consumer protection attorney to understand your options for compensation.
This is general information, not legal advice. Go Backs is not a law firm and does not provide legal services.
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.